about
Chemokine receptors and their therapeutic opportunities in diseased lung: far beyond leukocyte traffickingBlocking of monocyte chemoattractant protein-1 during tubulointerstitial nephritis resulted in delayed neutrophil clearanceAnalysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5.Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.Regio- and stereoselective syntheses of the natural product CCR5 antagonist anibamine and its three olefin isomers.C6-C8 bridged epothilones: consequences of installing a conformational lock at the edge of the macrocycle.The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets.CCR1 antagonists in clinical development.Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.Molecular requirements for inhibition of the chemokine receptor CCR8--probe-dependent allosteric interactions.Structure, function and physiological consequences of virally encoded chemokine seven transmembrane receptorsGenetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitorsAnti-chemokine small molecule drugs: a promising future?Chemokines and their receptors in the allergic airway inflammatory process.Tumor microenvironment: driving forces and potential therapeutic targets for breast cancer metastasisN-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338.A digest on the role of the tumor microenvironment in gastrointestinal cancers.Chemokine receptor modeling: an interdisciplinary approach to drug design.Blockade of CXCR2 signalling: a potential therapeutic target for preventing neutrophil-mediated inflammatory diseases.Role of Conserved Disulfide Bridges and Aromatic Residues in Extracellular Loop 2 of Chemokine Receptor CCR8 for Chemokine and Small Molecule BindingSymmetrical bis-tertiary amines as novel CXCR4 inhibitorsComparative docking study of anibamine as the first natural product CCR5 antagonist in CCR5 homology models.Profound anti-HIV-1 activity of DAPTA in monocytes/macrophages and inhibition of CCR5-mediated apoptosis in neuronal cells.Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.Synthesis of pyridine derivatives as potential antagonists of chemokine receptor type 4.Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo.Quantitative structure activities relationships of some 2-mercaptoimidazoles as CCR2 inhibitors using genetic algorithm-artificial neural networks.3D-QSAR studies on CCR2B receptor antagonists: Insight into the structural requirements of (R)-3-aminopyrrolidine series of molecules based on CoMFA/CoMSIA models.Reversed binding of a small molecule ligand in homologous chemokine receptors - differential role of extracellular loop 2.cCXCR1 is a receptor for cIL-8 (9E3/cCAF) and its N- and C-terminal peptides and is also activated by hIL-8 (CXCL8).Chemokines and atherosclerosis
P2860
Q27013008-CF9C2EBC-3CEC-4505-B636-3A82A083C256Q28574502-11ECFA44-6A2B-40D1-A70A-4CD93D1615A3Q34123627-47121E9F-E652-407A-9BAA-608CDDF04506Q34975941-D722D545-710D-4B65-9601-8F2A1E2661E7Q35400327-2AA2E742-8450-4B88-BC69-5DD551EA83BBQ35642476-46CCB977-2841-4C0E-8EAD-48CD2BE5694CQ35917148-30487B3F-E1BA-4415-B1AC-4A1C13014731Q36196440-8522E483-2E19-444B-935B-217D1187019FQ36371505-997F92B6-A5D0-4AB8-A9B0-CF907D83E4DEQ36419287-0ABC2833-EA0F-4B90-899A-CFD00CC04C02Q36497002-7C44D948-4173-413F-934C-CE7DD08E609BQ36509765-5D53E7B7-A89F-46F1-86DA-1C82AFDB63B5Q37079141-9C78BDF1-CCED-4D30-8A6D-B87CEA3BE122Q37092774-169E0C36-39FE-4810-B3F4-30DCAD153587Q37683772-2DC7F3E4-A04D-41CA-935A-198BFA25239FQ37721300-023D9FA9-86E1-422B-9A58-FD3BF4CFC4CCQ37728585-BE2B1662-3AB6-4FC9-8620-C2A3302B9033Q37790697-77EA089A-21C4-4F7D-B5E1-BDB95E47B6EAQ37826352-CFECFABE-1F13-438A-B36D-357FDA3AD0F7Q38172960-DA1BD07E-3BB6-48A9-9AA1-FA4F629AC4A5Q38195671-1B97A1DA-1331-47B7-BEAA-E869B00F503BQ38862301-63CB85C6-67A5-4CB7-9C58-E841614BFD47Q39766459-C112DA50-A285-4DEF-B3FA-F89CC61A5D51Q40007908-A297C5B4-A8DA-466A-9027-E71204F37746Q40042889-841356C7-3B4D-4CA2-9C8A-2ABA143AF061Q40277352-A2445B87-335E-498B-87D3-EB2A67DDD386Q41527702-93F64076-9A0C-421F-8817-A294CA9D0C5BQ41603563-5FEA2BDC-67A1-4763-8C2F-FA57241A68F7Q41761265-65C4F395-43EE-4844-B8E6-5CC60D8B479DQ42143606-A834E63E-2016-4A3C-9498-343C3C25F023Q42269169-2F12B121-5C9D-40B1-9A9D-4270D352C657Q42822920-01A0E30D-D802-4676-84E5-E5BE0339A779Q58246532-886F2471-4B02-4E63-8D7F-31A3BE4EFA17
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
New therapeutics that modulate chemokine networks.
@ast
New therapeutics that modulate chemokine networks.
@en
New therapeutics that modulate chemokine networks.
@nl
type
label
New therapeutics that modulate chemokine networks.
@ast
New therapeutics that modulate chemokine networks.
@en
New therapeutics that modulate chemokine networks.
@nl
prefLabel
New therapeutics that modulate chemokine networks.
@ast
New therapeutics that modulate chemokine networks.
@en
New therapeutics that modulate chemokine networks.
@nl
P2860
P356
P1476
New therapeutics that modulate chemokine networks.
@en
P2093
Matthias K Schwarz
Timothy N C Wells
P2860
P2888
P304
P356
10.1038/NRD795
P577
2002-05-01T00:00:00Z